All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-09-16T13:59:26.000Z

Is it possible to use different BCMA-targeted agents successively?

By Marta Llobet-Canela, Becky Gribbell, Erika Roa, Jennifer Higgins
Featured
María-Victoria Mateos
Sep 16, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM

Bookmark this article

During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to María-Victoria Mateos , University Hospital of Salamanca, Salamanca, ES. We asked, Is it possible to use different B-cell maturation antigen (BCMA)-targeted agents successively?

Is it possible to use different BCMA-targeted agents successively?

In this video, Mateos discusses the clinical outcomes of a cohort of 20 patients treated with different BCMA-targeted therapies sequentially. Mateos evaluates these outcomes in terms of minimal residual disease negativity rate, progression-free survival, and safety signals to come to a conclusion on the posed question.

More about...
BCMA CAR-TBelantamab mafodotinCAR therapyIMSIMS 2022Relapsed/refractory multiple myelomaT-cell engagers

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
19 votes - 12 days left ...

Related articles

Add bookmark

Efficacy and safety of ARI0002h, an academic BCMA-directed CAR T-cell therapy for RRMM

ARI0002h is a 4-1BB based CAR T-cell product containing a humanized single chain variable BCMA-targeting fragment with proven in vitro and in vivo efficacy. In...

Aug 5, 2022
Add bookmark

Efficacy and safety of ARI0002h, an academic BCMA-directed CAR T-cell therapy for RRMM

ARI0002h is a 4-1BB based CAR T-cell product containing a humanized single chain variable BCMA-targeting...

Aug 5, 2022
Add bookmark

Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, María‑Victoria Mateos chaired a recorded discussion that also featured Nina...

Jul 22, 2022
Add bookmark

Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, María‑Victoria Mateos chaired...

Jul 22, 2022

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox